Dexcom executive management
Board of directors
Steven R. Altman
Steven R. Altman joined the Dexcom Board of Directors in 2013. Up until his retirement from Qualcomm Incorporated in January 2014, Mr. Altman served as vice chairman of Qualcomm Incorporated and as a member of Qualcomm’s executive committee. In that role, Mr. Altman provided direction and guidance on key initiatives across all areas of the business, as well as on overall vision and strategy.
Mr. Altman joined Qualcomm in 1989 and was the chief architect of Qualcomm’s strategy for licensing its broad intellectual property portfolio for wireless communications, which has accelerated the growth of CDMA technology. In that role, he was responsible for structuring and negotiating Qualcomm’s license agreements, joint ventures, and strategic relationships. Under Mr. Altman’s leadership, Qualcomm entered into domestic and international licensing agreements with the world's largest telecommunications and electronics companies.
Mr. Altman began his career with the San Diego law firm of Gray, Cary, Ames & Frye (which later become DLA Piper), where he specialized in intellectual property, mergers and acquisitions, securities, and general corporate matters. He joined Qualcomm in 1989 as corporate counsel with responsibility for licensing and contracts, quickly moving up through the management ranks and becoming vice president and general counsel in 1992. He became general manager of QTL when that organization was formed in 1995; and senior vice president in 1996. In 1998, Mr. Altman was named executive vice president; and president of QTL in 2000. From 2005 to 2011, Mr. Altman served as the president of Qualcomm where his leadership and contributions helped enable Qualcomm’s successful growth, evolution, and expansion.
Mr. Altman graduated from Northern Arizona University in 1983 with a bachelor’s degree in political science and administration; he received his Juris Doctor from the University of San Diego School of Law in 1986. Mr. Altman served as a board member of Ubiquiti Networks, Inc. from October 2013 to December 2015. He is also a member of the University of California at San Diego (UCSD) Health Board of Advisors. Mr. Altman also serves as a board member for privately-held company, Brain Corporation. As a former board member of the Juvenile Diabetes Research Foundation (JDRF), he remains an active supporter of the JDRF and numerous other charitable causes.
Nick Augustinos
Nicholas (Nick) Augustinos has served on our Board since November 2009. Nick was the President & CEO of Aver, Inc. dba Enlace Health a company specializing in Value-Based Reimbursement, Analytics and Payment Solutions. Besides his role as President & CEO Nick serves on the Board of Directors of Aver, Inc. Prior to Aver, Inc., Nick was the Senior Vice President, Health Information Services and Strategy, at Cardinal Health (NYSE: CAH). In January 2015, he was appointed to the Board of Directors of the California Health Care Foundation (CHCF). CHCF is an endowed foundation that has as its mission to improve care for all Californians through innovations that improve quality, increase efficiency, and lower the cost of care. He serves at the Finance & Investment Committee and the Governance Committee which he chaired for 3 years. Prior to CHCF Nick served on the Board of Directors of the SCAN Foundation (June 2011 - December 2014), an endowed foundation dedicated to advancing the development of a sustainable continuum of quality care for seniors. Nick served on the Board of Directors of Audax Health, now Rally (March 2012 - February 2014), specializing in consumer engagement solutions. Rally is currently part of Optum, a UnitedHealth Group company. In 1992 Mr. Augustinos joined Deloitte Consulting where he was instrumental in establishing the healthcare practice for Northern California. In 1998 Mr. Augustinos joined Healtheon/WebMd (NASDQ: HLTH) a healthcare information technology company. Nick led the Customer Experience team. Nick brings 38 years of broad managerial, consulting, and business development experience in the private and public sector. He has worked with a diverse range of leading healthcare delivery systems, healthcare insurers, and government organizations globally.
Prior to Cardinal Health, Nick was the Senior Director for Global Healthcare Operations at Cisco Systems, (NASDAQ: CSCO), leading the go to market strategy for healthcare focusing on public sector bringing business and technical expertise along with thought leadership in the areas of connected health, wellness, and care delivery. Nick started his career at Cisco as the Senior Director for Global Healthcare Solutions of the Internet Business Solutions Group – the strategic consulting business unit of Cisco. He led among other initiatives the Cisco HealthPresence™ development, Cisco’s core telemedicine platform.
Prior to Cisco, Nick was Partner and Senior Strategic Consulting Expert, Global Health Services, for CSC. Prior to joining CSC, he was Vice President, Care Data Exchange business unit for CareScience, leading product development and services in the clinical document exchange space. Nick was also Vice President for Healtheon/WebMD, responsible for Customer Experience, Marketing & Sales for the company’s products and services. Prior to that, he was with Deloitte Consulting and was instrumental in establishing the healthcare practice for Deloitte’s San Francisco office, managing numerous projects for payers, providers, and integrated delivery networks. He started his career in healthcare as Vice President, Administration, of CliniShare.
Richard Collins
Richard Collins has served on our Board since March 2017.
Mr. Collins has been a self-employed consultant since October 2013. From March 2011 to October 2013 Mr. Collins was the Chief Executive Officer for UnitedHealthcare’s Northeast Region and was at different times the President, Director or Chairman of numerous UnitedHealthcare subsidiaries including Oxford Health Plans, Mid Atlantic Medical Services and UHC Insurance Company of New York. From July 2005 through December 2012 Mr. Collins served as President – Individual Line of Business for UnitedHealthcare and as the Chairman and Chief Executive Officer of Golden Rule Financial Corporation. Prior to 2011, Mr. Collins also held leadership positions in pricing, underwriting and healthcare economics with UnitedHealthcare. During his tenure there, Mr. Collins saw UnitedHealthcare grow from a mid-cap health insurer into one the largest public corporations in America.
Mr. Collins has previously served on the Boards of Fairbanks Hospital in Indianapolis, Indiana, The Indiana Chapter of The Nature Conservancy, UnitedHealthcare Children’s Foundation, and the Council for Affordable Health Insurance.
Mr. Collins brings significant experience in healthcare insurance and administration to our Board.
Karen Dahut
As CEO of Google Public Sector (GPS), Ms. Karen Dahut helps U.S. state, local, and federal agencies, and educational institutions accelerate their digital transformations. With her charge leading GPS, she works to bring Google technology to solve complex problems for U.S. public sector institutions. These technologies include Google’s data analytics and artificial intelligence (AI) platform; infrastructure services for storage, compute, and networking; cybersecurity solutions; and Google Workspace for collaboration and communication.
Karen was previously sector president at Booz Allen Hamilton, where she led the company’s $4 billion global defense business—representing half of the firm’s annual revenue—and global commercial business sector, which delivered next-generation cybersecurity solutions to Fortune 500 companies. Under her leadership, Booz Allen became the premier digital integrator, helping federal agencies use technology in support of their missions.
Karen also has deep experience in building innovative solutions that help organizations tackle their toughest challenges. For example, at Booz Allen, she served as chief innovation officer and built the firm’s Strategic Innovation Group, which delivered new capabilities in cybersecurity, data science, and digital technologies.
Karen began her career as an officer in the U.S. Navy and served as the controller for the Navy’s premier biomedical research institute.
A respected and recognized public speaker and author, she’s an expert on technology, the future of work, innovation, and inclusive leadership.
Also an experienced board director for nonprofit and private organizations, she serves on the boards of Dexcom, Eisner Advisory Group, and previously served on Tech Data Corporation’s board. She is a trustee of the Smithsonian’s National Air and Space Museum and serves as a board member for the Viterbi School of Engineering, Department of Computer Science, University of Southern California.
Karen received a bachelor’s of science degree in finance from Mount St. Mary's University and a master’s degree in systems management from the Viterbi School of Engineering, University of Southern California. She lives in Bethesda, Md., with her family.
Mark Foletta
Mark Foletta has considerable audit and financial experience in the biotechnology and pharmaceutical sectors. Mr. Foletta previously served as Senior Vice President, Finance and Chief Financial Officer of Amylin Pharmaceuticals, Inc., a public pharmaceutical company, from March 2006 through Amylin’s acquisition by Bristol Myers-Squibb Company in August 2012, and as Vice President, Finance and Chief Financial Officer of Amylin from 2000 to 2006. Prior to joining Amylin in 2000, Mr. Foletta held a number of management positions with Intermark, Inc. and Triton Group Ltd. from 1986 to 2000 and served as an Audit Manager with Ernst & Young. Mr. Foletta served as a director of Anadys Pharmaceuticals, Inc., a publicly-held biopharmaceutical company now owned by F. Hoffmann-La Roche Inc., from September 2005 through November 2011. He is currently a member of the Board of Directors and Audit Committee of AMN Healthcare Services, Inc., a publicly traded healthcare workforce solutions provider, and Regulus Therapeutics, Inc., a publicly traded biopharmaceutical company. Mr. Foletta received a B.A. in Business Economics from the University of California, Santa Barbara and is a member of the Corporate Directors Forum.
Bridgette Heller
Bridgette Heller has served on the Board since September 2019. Ms. Heller brings to our Board considerable experience in business, specifically as it relates to technology and manufacturing, and she is a strong addition to the Board as Dexcom continues to expand and scale its operations.
Ms. Heller is a co-founder and the CEO of a small nonprofit, the Shirley Proctor Puller Foundation, committed to generating better educational outcomes for underserved children in St. Petersburg, Florida. Previously, Ms. Heller served as the EVP and President of Nutricia, the Specialized Nutrition Division of Danone from July 2016 to August 2019. From 2010 to 2015, she served as Executive Vice President of Merck & Co., Inc. and President of Merck Consumer Care. Prior to joining Merck, Ms. Heller was President of Johnson & Johnson’s Global Baby Business Unit from 2007 to 2010 and President of its Global Baby, Kids, and Wound Care business from 2005 to 2007. She also worked for Kraft Foods from 1985 to 2002, ultimately serving as Executive Vice President and General Manager for the North American Coffee Portfolio.
Ms. Heller also serves on the Boards of Novartis and Tech Data Corporation.
She holds an MBA from Northwestern University’s Kellogg Graduate School of Management and is a member of the school’s Advisory Board. Ms. Heller received her bachelor’s degree in Economics and Computer Studies from Northwestern University.
Kyle Malady
Kyle Malady joined the Dexcom Board of Directors in 2020. Mr. Malady currently serves as executive vice president of global networks and technology & chief technology officer at Verizon Communications Inc. In this role, Mr. Malady leads the company’s network operations, IT functions, data center management, and customer facing new product realization.
Prior to assuming this role, Mr. Malady was head of the Core Engineering and Operations organization within the Global Network and Technology organization. He has also served as Verizon’s vice president of New Product Development, including an instrumental role in the development and commercialization of 4G LTE
In addition to his experience at Verizon, Mr. Malady manages Caelens Fund, a charity that raises money to provide free cardiac surgeries for children in developing countries. Mr. Malady holds an MBA in finance from the NYU Stern School of Business and Bachelor of Science in Mechanical Engineering from the University of Bridgeport.
Kevin Sayer
Kevin Sayer is the Chairman of the Board of Directors, President and Chief Executive Officer of Dexcom
Kevin assumed the role of CEO in January 2015 and became Chairman of the Board in July 2018. Kevin has also served as our President since 2011. He held the role of Chief Operating Officer from January 2013 until January 2015. Kevin has served as a member of Dexcom’s Board of Directors beginning in November 2007, prior to his role as Chairman and CEO.
Prior to leading Dexcom, Kevin held various management positions in his prior roles. He served as Chief Financial Officer of Biosensors International Group, Ltd., Executive Vice President and Chief Financial Officer of Specialty Laboratories, Inc., Chief Financial Officer of MiniMed, Inc., and Vice President and General Manager of Medtronic MiniMed after the acquisition of MiniMed by Medtronic.
Kevin is a Certified Public Accountant (inactive) and received a Bachelor’s degree and a Master's degree in Accounting and Information Systems from Brigham Young University.
Eric J. Topol, M.D.
Eric J. Topol, M.D. is the Director of the Scripps Translational Science Institute, a National Institutes of Health funded program of the Clinical and Translational Science Award (CTSA) Consortium. In 2009, he was named the Gary and Mary West Endowed Chair of Innovative Medicine. He is Executive Vice President and Professor of Molecular Medicine at The Scripps Research Institute and a Senior Consultant cardiologist practitioner at Scripps Clinic.
Prior to coming to Scripps, he served on the faculty of Case Western as a professor in genetics, chaired the Department of Cardiovascular Medicine at Cleveland Clinic for 15 years and raised its status to rank #1 by US News and World Report for 11 consecutive years, and founded the Cleveland Clinic Lerner College of Medicine. His work in the genomics of heart attack has led to discovery of key genes (MEF2A deletion, THSB-4 variant) which led to recognition by the American Heart Association top 10 research advances in 2002 and 2004. As a leader in clinical trials of novel therapeutics, he administered recombinant t-PA to the first patient in 1984, pioneered and led the clinical development of clopidogrel (Plavix), bivalirudin (Angiomax), and abciximab (ReoPro). He has over 1,100 original peer reviewed publications, and has edited over 30 books, including the Textbook of Interventional Cardiology (5th ed), and the Textbook of Cardiovascular Medicine (3rd ed). Dr. Topol has been elected to the Institute of Medicine of the National Academy of Sciences, the American Association of Physicians and recognized by the Institute of Scientific Information (ISI) to be in the top 10 cited biomedical researchers in medicine in the past decade.
Dr. Topol has also been a medical innovator in digital medicine, having authored two best seller books on the topic – The Creative Destruction of Medicine (2012) and The Patient Will See You Now (2015).
Rimma Driscoll
Rimma Driscoll joined the Dexcom Board of Directors in 2023. Ms. Driscoll is an accomplished leader with significant experience developing, guiding, and executing organic and inorganic growth strategies for global organizations. She brings to the Dexcom Board a track record of impactful leadership across the global healthcare, consumer, and animal health industries, including the successful completion of transformative transactions and key product launches.
Ms. Driscoll joined Zoetis, the world’s leading animal health company and a member of the Fortune 500, in 2016 and currently serves as Executive Vice President and Head of Global Strategy, Commercial and Business Development, and Global BioDevices. In this role, Ms. Driscoll oversees the company’s global business strategy, the execution of commercial launch plans, external business development (M&A) and integration efforts, and has oversight for Zoetis’ Global BioDevices business. Under her leadership, Zoetis has successfully completed key acquisitions and partnerships to accelerate the company’s geographic expansion and growth in areas such as diagnostics, precision animal health, and genetics. In addition, she has partnered across the business to advance innovation and identify investment opportunities that complement and strengthen the company’s product portfolio in various therapeutic areas.
Prior to joining Zoetis, Ms. Driscoll spent 21 years at Procter & Gamble where she led global business development and strategic alliances across multiple businesses in pharmaceuticals, consumer healthcare, beauty care, and new business ventures. Her global expertise spanned a broad range of transactions from acquisitions to strategic alliances, joint ventures, partnerships, and divestitures. Ms. Driscoll held leadership roles in the US and in Geneva, Switzerland.
Additionally, Ms. Driscoll is a board member of Pumpkin Insurance, a preventive care and pet insurance company. Ms. Driscoll completed her Master of Business Administration from Xavier University, Williams College of Business, and her Bachelor of Science in Chemistry from Bowling Green State University.